Abstract: In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of (i) mesenchymal stem cells (MSCs) or secretome from MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGF?1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); (ii) exosomes produced by MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGF?1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); and/or (iii) exosomes comprising one or more effectors, wherein the one or more effectors comprises, consists essentially of, or consists of (a) miR144, (b) BMP-2, (c) TGF?1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d), and wherein the amount of the effector per exosome is greater than the amount of the effector per exosome when produced by unmodified MSCs.

Abstract: In aspects, the present disclosure provides a method of treating or preventing uterine fibroids (UF) or polycystic ovary syndrome (PCOS) in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of doxercalciferol. In aspects, the present disclosure provides a method of treating insulin resistance, infertility, obesity, and/or hyperandrogenism related to PCOS in a female mammal.

Abstract: In aspects, the present disclosure provides a method of treating or preventing a uterine leiomyosarcoma in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an inhibitor of bromodomain-containing protein 9 (BRD9).

Abstract: In aspects, the disclosure provides a method of differentiating a malignant tumor from a non-malignant tumor in a mammal having a tumor comprising determining in a sample from the mammal the level of one or more of: (1) transthyretin (TTR) RNA or protein, (2) dual oxidase 2 (DUOX2) RNA or protein, and (3) G-protein coupled receptor 179 (GPR179) RNA or protein.

Abstract: In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an inhibitor of bromodomain (BRD) protein.

Abstract: In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an agent that modulates an N6-methyladenosine (m6A) regulator.

Abstract: This invention provides compositions of a viral vector system containing a survivin promotor configured for expressing a reporter gene, wherein the reporter gene is differentially expressed in benign and malignant uterine masses and malignant uterine sarcomas can be bioimaged by preferential labeling with a radiotracer.

Abstract: Compositions and methods for the detection and treatment of cancer are provided. It has been discovered that uterine cancer cells selectively induce the survivin promoter to express a gene product. One embodiment provides a method for detecting uterine malignancy by systemic administration of a cancer-specific vector that utilizes a Survivin promoter to drive expression of a reporter gene. The expression of the reporter gene is detectable exclusively in malignant cells, for example using conventional imagining techniques.

Abstract: Methods and compositions for treating ovarian failure are provided. In one embodiment, the method includes administering stem cells into the ovary of a female subject in need of such treatment. The stem cells are preferably bone marrow derived stem cells (BMSC). In other embodiments, the stem cells are embryonic stem cells, adult stem cells, induced stem cells, induced pluripotent stem cells, umbilical cord blood cells, or combinations thereof. The stem cells can be autologous or heterologous. In one embodiment, the stem cells have the following surface marker profile: CD105 positive, CD166 positive, CD90 positive, and CD73 positive as well as CD14 negative, CD34 negative, CD45 negative, HLA-DR negative, and CD 19 negative. The stem cells are administered in an amount effective to restore ovarian hormone production and promote folliculogenesis.

Abstract: Compositions and methods for the detection and treatment of cancer are provided. It has been discovered that uterine cancer cells selectively induce the survivin promoter to express a gene product. One embodiment provides a method for detecting uterine malignancy by systemic administration of a cancer-specific vector that utilizes a Survivin promoter to drive expression of a reporter gene. The expression of the reporter gene is detectable exclusively in malignant cells, for example using conventional imagining techniques.

Abstract: The present invention relates to an association between specific polymorphisms of the COMT polypeptide and the development, or risk of developing, preterm labor and uterine diseases and conditions. Disclosed are therapeutic, preventative and diagnostic methods and compositions relating to pre-term labor, uterine diseases and conditions, and ovarian conditions and diseases. In certain embodiments, such methods and compositions involve a COMT inhibitor.

Abstract: The present invention relates to an association between specific polymorphisms of the COMT polypeptide and the development, or risk of developing, preterm labor and uterine diseases and conditions. Disclosed are therapeutic, preventative and diagnostic methods and compositions relating to pre-term labor, uterine diseases and conditions, and ovarian conditions and diseases. In certain embodiments, such methods and compositions involve a COMT inhibitor.

Abstract: The present invention relates to an association between specific polymorphisms of the COMT polypeptide and the development, or risk of developing, preterm labor and uterine diseases and conditions. Disclosed are therapeutic, preventative and diagnostic methods and compositions relating to pre-term labor, uterine diseases and conditions, and ovarian conditions and diseases. In certain embodiments, such methods and compositions involve a COMT inhibitor.

Abstract: The present invention provides methods of treating and preventing uterine fibroids that is non-surgical, using a modified estrogen receptor gene delivered via an adenoviral vector. The modified estrogen receptor induced apoptosis in vitro and decreased tumor growth in vivo. The invention provides a major improvement above that of current available procedures for women having uterine fibroids, or in preventing fibroids in women at risk of having fibroids. The present invention further provides a safe means of treating fibroids and preserving fertility in young women, or maintaining pregnancy in pregnant women having fibroids.